Relmada Therapeutics (RLMD) Starts Presentation at LD Micro Main Event
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, biotechnology company developing adaptations of proven drug products with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. The company has four products at various stages of development: d-Methadone (dextromethadone, REL-1017), LevoCap ER (REL-1015), oral buprenorphine (BuTab, REL-1028) and (MepiGel, REL-1021). The company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products to address areas of high unmet medical needs. For more information, visit the company's website at www.relmada.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news…







